| Review of major intervention studies in hypertension and hyperlipidemia: focus on coronary heart disease. | |
| | |
MedLine Citation:
|
PMID: 3059787 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The ultimate aim in treating hypertension and hyperlipidemia is to reduce cardiovascular mortality and morbidity, especially strokes and coronary events, for example, fatal and nonfatal myocardial infarction and sudden death. Extensive intervention studies in moderate-to-severe hypertension have revealed the significance of antihypertensive therapy in reducing total cardiovascular mortality and morbidity, particularly from cerebrovascular causes. However, the reduction of coronary events has not been equally successful. The situation in mild-to-moderate hypertension is even more disappointing: recent studies, such as the Medical Research Council hypertension trial, the international Prospective Primary Prevention Study in Hypertension, and the Heart Attack Primary Prevention in Hypertensives trial could not demonstrate any benefit from antihypertensive treatment with beta-blockers or diuretics in the prevention of coronary heart disease. The reasons for these negative results are not obvious. However, metabolic side effects associated with certain antihypertensive drugs, which counteract the beneficial effects of blood pressure reduction, are one topic of discussion. For the genesis of atherosclerosis of the coronary vasculature, hyperlipoproteinemia appears to be of greater importance than hypertension and has to be treated simultaneously. Two extensive intervention studies, the Lipid Research Clinics coronary primary prevention trial and the Helsinki Heart Study, showed a significant reduction of coronary events with lipid-lowering treatments with cholestyramine and gemfibrozil, respectively. These findings are in agreement with the results of a recent secondary prevention study, which showed a regression of atherosclerosis in coronary arteries and aortocoronary bypass grafts. Moreover, antihypertensive treatment aimed at a reduction in coronary heart disease has to focus on serum lipids, especially in mild hypertension.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
M Middeke; H Holzgreve |
Related Documents
:
|
12626307 - The association of plasma homocysteine, coronary risk factors and serum nitrite in pati... 16970947 - In vivo coronary plaque histology in patients with stable and acute coronary syndromes:... 15757077 - Effect of preexisting statin use on expression of c-reactive protein, adhesion molecule... 16214597 - Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of dat... 16226107 - Myocyte changes and their left atrial distribution in patients with chronic atrial fibr... 7882477 - Occult and frequent transmission of atherosclerotic coronary disease with cardiac trans... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American heart journal Volume: 116 ISSN: 0002-8703 ISO Abbreviation: Am. Heart J. Publication Date: 1988 Dec |
Date Detail:
|
Created Date: 1989-01-17 Completed Date: 1989-01-17 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1708-12 Citation Subset: AIM; IM |
Affiliation:
|
Medical Policlinic, University of Munich, West Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Coronary Disease / etiology, prevention & control* Female Humans Hyperlipidemias / complications, drug therapy* Hypertension / complications, drug therapy* Male Middle Aged |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of bone marrow ablation on compartmental prostaglandin synthesis by mononuclear phagocytes.
Next Document: Effects of antihypertensives on plasma lipids and lipoprotein metabolism.